Preceding bortezomib administration for a certain period reduces the risk of lenalidomide‐induced skin rash

• Published in: Journal of Clinical Pharmacy and Therapeutics Vol. 47; no. 4; pp. 477 - 482
• Main Authors: Sugi, Tomiyuki, Mita, Mitsuo, Yasu, Takeo, Kubo, Kana, Kushi, Ryota, Hanai, Homare, Ohara, Shin, Uchida, Tomoyuki, Inoue, Morihiro, Hagihara, Masao
• Format: Journal Article
• Language: English
• Published: England Hindawi Limited 01.04.2022; John Wiley & Sons, Inc
• Subjects: Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Bortezomib; Bortezomib - adverse effects; Dexamethasone; Dexamethasone - therapeutic use; Exanthema; Exanthema - chemically induced; Exanthema - epidemiology; Exanthema - prevention & control; Humans; Immunotherapy; Inhibitor drugs; Investigations; Lenalidomide; Lenalidomide - adverse effects; Multiple Myeloma; Multiple Myeloma - drug therapy; Multivariate analysis; Patients; Retrospective Studies; Skin; skin rash; Targeted cancer therapy; skin rash; bortezomib; lenalidomide

What is known and objective It was previously reported that the incidence of lenalidomide (LEN)‐induced skin rash is reduced by administration of bortezomib (BOR) prior to LEN administration in patients with multiple myeloma (MM). Therefore, we investigated whether LEN‐induced skin rash is affected...